https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/news

The Latest

selective focus image of Gilead Truvada for PrEP

This Week in HIV Research: PrEP So White

May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

Vaccination being filled

Investigational PrEP Injection, Dosed Every Other Month, Holds Up Against Daily PrEP in Phase 3 Study

The long-acting injectable drug cabotegravir proved non-inferior to daily oral TDF/FTC for MSM and transgender women.

PrEP prescription

CDC Issues New Guidance for Easier PrEP Access During COVID-19

Home HIV and STI testing is now being endorsed by the Centers for Disease Control and Prevention to start or continue pre-exposure prophylaxis (PrEP).

gay men in COVID-19 times

COVID-19 Impacts Gay and Bisexual Men's Mental Health, Sexual Behavior, and Access to HIV/STI Services

This new study is the first to look at the impacts of the coronavirus pandemic on men who have sex with men.

data

This Week in HIV Research: There’s No Such Thing as Too Much Data

May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.

fast pace of life

This Week in HIV Research: Special Considerations

April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.

integrase inhibitor

This Week in HIV Research: The Fast-Acting Power of Integrase

April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.

lab testing

This Week in HIV Research: The Frustrating Relativity of Efficacy

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

blue pills on blue background

This Week in HIV Research: PrEP Relief

Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.

long winding road through countryside

This Week in HIV Research: The Long Road to the End

Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.